✦ LIBER ✦

KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?

✍ Scribed by M. HEBBAR; P. FOURNIER; O. ROMANO

Book ID: 108710814
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 73 KB
Volume: 19
Category: Article
ISSN: 0961-5423
DOI: 10.1111/j.1365-2354.2009.01134.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Different metastatic pattern according t

Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer

✍ Mi-Jung Kim, Hye Seung Lee, Jee Hyun Kim, Yu Jung Kim, Ji Hyun Kwon, Jeong-Ok Le 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 206 KB

KRAS mutations are associated with infer

KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib

✍ Smith, John C.; Brooks, Laura; Hoff, Paulo M.; McWalter, Gael; Dearden, Simon; M 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 590 KB

The KRAS mutation detection within the i

The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: A status report in France in 2011

✍ Lièvre, A.; Artru, P.; Guiu, M.; Laurent-Puig, P.; Merlin, J.L.; Sabourin, J.C.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 809 KB

Association of K-ras Mutational Status a

Association of K-ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone

✍ Daniel J. Freeman; Todd Juan; Maureen Reiner; J. Randolph Hecht; Neal J. Meropol 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 502 KB

Association of K-ras Mutational Status a

Association of K-ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone

✍ Daniel J. Freeman; Todd Juan; Maureen Reiner; J. Randolph Hecht; Neal J. Meropol 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 502 KB

Background: Identifying predictive biomarkers is important to optimally treat patients. This analysis evaluated the association of K-ras, BRAF, and PIK3CA gene mutations with tumor resistance to panitumumab alone. Patients and Methods: From 3 phase II panitumumab metastatic colorectal cancer (mCRC)

6136 POSTER Relatively High Discordant R

6136 POSTER Relatively High Discordant Rate of KRas Mutation Between Primary and Metastatic Sites, and a Different Pattern of KRas Mutational Status According to Metastatic Sites in Korean Patients With Colorectal Cancer

✍ Kim, M.J.; Lee, K.W.; Lee, H.S.; Kim, J.H.; Kim, Y.J.; Kwon, J.H.; Kim, D.W.; Ka 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 41 KB